Sugi Predict

Sugi Predict / Compounds / SCHEMBL14931691

SCHEMBL14931691

SCHEMBL14931691

COc1ccc(-c2c3c(=O)n(-c4ccccc4OC)[nH]c3cc(=O)n2Cc2cccnc2)c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NOX4 Q9NPH5 17/20 0.51
▸ CYBB P04839 10/20 0.51
▸ NOX5 Q96PH1 9/20 0.48
▸ NOX1 Q9Y5S8 9/20 0.48
▸ GABRA1 P14867 1/20 0.42
▸ GABRA5 P31644 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C8 P10632 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29523256 1.00 NOX4 (0.51) NOX4CYBBNOX5NOX1GABRA1
SCHEMBL29523126 0.94 NOX4 (0.51) NOX4CYBBNOX5NOX1GABRA1
SCHEMBL14931684 0.94 NOX4 (0.51) NOX4CYBBNOX5NOX1GABRA1
SCHEMBL29523385 0.92 NOX4 (0.51) NOX4CYBBNOX5NOX1CYP3A4
SCHEMBL14931723 0.92 NOX4 (0.51) NOX4CYBBNOX5NOX1CYP3A4
SCHEMBL29523450 0.91 NOX4 (0.53) NOX4CYBBNOX5NOX1CYP3A4
SCHEMBL14931690 0.91 NOX4 (0.53) NOX4CYBBNOX5NOX1CYP3A4
SCHEMBL29523655 0.88 NOX4 (0.54) NOX4CYBBNOX5NOX1GABRA1
SCHEMBL14931680 0.88 NOX4 (0.54) NOX4CYBBNOX5NOX1GABRA1
SCHEMBL14931671 0.87 NOX4 (0.51) NOX4CYBBNOX5NOX1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021079-A1 NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-01-22 — — US claimed
WO-2023217764-A1 NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2023-11-16 — — WO claimed
US-20210177811-A1 USE OF NOX INHIBITORS FOR TREATMENT OF CANCER CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2021-06-17 — — US claimed
US-20210060051-A1 COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS EMORY UNIVERSITY 2021-03-04 — — US claimed
CN-111971284-A COMBINATION MODES OF NUCLEOSIDE AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELLIS-SPECIFIC ANTIVIRAL AGENTS 埃默里大学 2020-11-20 — — CN claimed
EP-3732180-A1 COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS Emory University (US) 2020-11-04 — — EP claimed
CN-111344013-A Use of NOX inhibitors for the treatment of cancer 吉恩基奥泰克斯瑞士股份有限公司 2020-06-26 — — CN claimed
EP-3479843-A1 USE OF NOX INHIBITORS FOR TREATMENT OF CANCER GenKyoTex Suisse SA (CH) 2019-05-08 — — EP claimed
EP-2776027-B1 NADPH OXIDASE 4 INHIBITORS AND USE THEREOF GENKYOTEX SUISSE SA (CH) 2017-06-07 — — EP claimed
US-20140323500-A1 NADPH OXIDASE 4 INHIBITORS AND USE THEREOF Johann Wolfgang Goethe-Universität (DE) 2014-10-30 — — US claimed
EP-2776027-A1 NADPH OXIDASE 4 INHIBITORS AND USE THEREOF GENKYOTEX SA (CH) 2014-09-17 — — EP claimed
WO-2013068972-A1 NADPH OXIDASE 4 INHIBITORS AND USE THEREOF Johann Wolfgang Goethe-Universität (DE) 2013-05-16 — — WO claimed
EP-2591782-A1 Nadph oxidase 4 inhibitors and use thereof Johann Wolfgang Goethe-Universität (DE) 2013-05-15 — — EP claimed
US-20260021079-A1 NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-01-22 — — US disclosed
EP-3980400-B1 PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS UNIV EMORY (US) 2025-08-06 — — EP disclosed
US-20250114389-A1 NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS UNIV EMORY (US) 2025-04-10 — — US disclosed
WO-2013068972-A1 NADPH OXIDASE 4 INHIBITORS AND USE THEREOF Johann Wolfgang Goethe-Universität (DE) 2013-05-16 — — WO disclosed
WO-2013068972-A1 NADPH OXIDASE 4 INHIBITORS AND USE THEREOF Johann Wolfgang Goethe-Universität (DE) 2013-05-16 — — WO disclosed
EP-2591782-A1 Nadph oxidase 4 inhibitors and use thereof Johann Wolfgang Goethe-Universität (DE) 2013-05-15 — — EP disclosed
EP-2591782-A1 Nadph oxidase 4 inhibitors and use thereof Johann Wolfgang Goethe-Universität (DE) 2013-05-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021079-A1 NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME NOX1, NOX5, NOX4 NOX4 3/4885CYBB 6/4885NOX5 2/4885
US-20210060051-A1 COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS NOX1, NOX3, NOX4 NOX4 3/4885CYBB 6/4885NOX5 4/4885
US-20250114389-A1 NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS PNP, MTAP, NOP2 NOX4 3555/4885CYBB 4048/4885NOX5 2890/4885
US-20140323500-A1 NADPH OXIDASE 4 INHIBITORS AND USE THEREOF NOX4, NOX1, NOX5 NOX4 1/4885CYBB 6/4885NOX5 3/4885
US-20210177811-A1 USE OF NOX INHIBITORS FOR TREATMENT OF CANCER NOX1, NOX5, NOX3 NOX4 5/4885CYBB 6/4885NOX5 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback